Steven Borg joins as CTO, David McGovern as Vice President of Marketing, and Jim Hartman advances to CCO to support company's mission to create a world without heart attacks
DENVER – August 22, 2024 -- Cleerly, the company on a mission to create a new standard of care for heart disease, is pleased to announce the appointment of industry veteran Steven Borg as Chief Technology Officer, the addition of David McGovern as Vice President of Marketing, and the promotion of Jim Hartman from Chief Revenue Officer to Chief Commercial Officer.
"We are thrilled to welcome Steven and David, as well as congratulate Jim on his well-deserved promotion. Their skills and expertise will undoubtedly strengthen Cleerly's position as an industry leader and drive our mission to revolutionize cardiovascular care,” said Dr. James Min, Founder and CEO of Cleerly. “With the addition of Steven and David, and the promotion of Jim, we are confident that our world-class clinical, commercial, and technical teams will further enhance health literacy for everyone in the coronary care pathway."
Steven Borg is a technology industry leader and innovator with 23 years of experience driving organizational transformation. He previously served as Chief Technology Officer at 3motion.ai and Senior Director of Health Data and AI at Microsoft. Borg’s expertise in Artificial Intelligence and his innovative technical vision will be instrumental as he leads Cleerly's technology initiatives.
David McGovern joins Cleerly as the Vice President of Marketing, bringing over 30 years of diverse marketing and commercial leadership experience in the life science and healthcare industry. His previous roles include Senior Vice President of Marketing at SomaLogic and leadership positions at Pfizer, Change Healthcare, and several multinational biotechnology organizations. McGovern's extensive experience in driving innovative healthcare software, analytics, and service solutions will be invaluable in elevating Cleerly's marketing strategy.
Jim Hartman's exceptional leadership and strategic vision have been instrumental in accelerating sales and expanding Cleerly's market presence since joining in 2021. With his promotion to Chief Commercial Officer, Hartman will continue to leverage his extensive experience in developing high-performing sales teams and executing strategic business plans to further drive Cleerly's commercial success.
These strategic appointments reflect Cleerly's commitment to assembling an elite team to drive innovation and growth, further solidifying its position as a leader in the healthcare technology sector. They join Cleerly at an exciting time of growth after achieving FDA approval, expanding nationally, and significantly growing physician usage and coronary artery disease analysis.
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: www.cleerlyhealth.com.
